BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 122 filers reported holding BRIDGEBIO PHARMA INC in Q2 2020. The put-call ratio across all filers is 0.03 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $1,406,000 | -70.3% | 30,000 | -61.3% | 0.18% | -55.6% |
| Q2 2021 | $4,730,000 | -8.4% | 77,600 | -7.4% | 0.41% | -27.6% |
| Q1 2021 | $5,162,000 | +476.1% | 83,801 | +565.1% | 0.57% | +439.0% |
| Q4 2020 | $896,000 | +89.4% | 12,600 | 0.0% | 0.10% | +50.0% |
| Q3 2020 | $473,000 | +15.1% | 12,600 | 0.0% | 0.07% | -48.9% |
| Q2 2020 | $411,000 | -21.3% | 12,600 | -30.0% | 0.14% | -43.9% |
| Q1 2020 | $522,000 | -17.3% | 18,000 | 0.0% | 0.24% | -36.1% |
| Q4 2019 | $631,000 | -36.8% | 18,000 | -61.3% | 0.38% | -27.7% |
| Q3 2019 | $999,000 | -38.3% | 46,548 | -22.4% | 0.53% | +47.1% |
| Q2 2019 | $1,618,000 | – | 60,000 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |